Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment
Future Oncology · 01.01.2023 · 19 (3) · 259-270
DOI: 10.2217/fon-2022-0826 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Oncology, online erschienen am 09.03.2023. Verfasst von Chuhan Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, the First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, 215000, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: the Translational Research Grant of NCRCH, Gusu Medical Talent of Suzhou City, Suzhou science and technology development project.
Abstract (Originalsprache)
Aim
To investigate the computed tomography (CT) and clinical characteristics of immunotherapy-induced pneumonitis (IIP) in patients with advanced solid tumors. Patients & methods: CT and clinical data of 254 patients with advanced solid tumors treated with immune checkpoint inhibitors in our hospital were collected retrospectively.
Results
The incidences of IIP in patients with non-small-cell lung cancer, lymphoma and gastrointestinal tumors were 19% (19/100), 9.8% (6/61) and 6.2% (4/65), respectively. The median onset time for all 31 IIP patients was 44 days (interquartile range: 24-65). Most IIP patients (21/31) had grade 1-2 disease. Multifocal ground-glass opacities (seen in 21/31 patients) were the main CT findings of IIP.
Conclusion
Patients should be alerted to the risk of IIP, an adverse reaction that has a relatively low incidence but which is sometimes life-threatening. The study aimed to investigate the clinical and computed tomography (CT) features of immunotherapy-induced pneumonitis (IIP) in patients with advanced solid tumors. To describe these characteristics, clinical and CT information of 254 patients with advanced solid tumors who were treated with drugs called immune checkpoint inhibitors were collected. The incidences of IIP in patients with non-small-cell lung cancer, lymphoma and gastrointestinal tumors were 19% (19/100), 9.8% (6/61) and 6.2% (4/65), respectively. The median time taken to develop IIP for all 31 IIP patients was 44 days. Most IIP patients had mild or moderate (grade 1–2) disease. The main CT findings of IIP were abnormalities called multifocal ground-glass opacities (21/31). Most IIP patients can recover well after glucocorticoid discontinuation. This real-world study was done to raise physicians’ awareness of the possible development of IIP, an adverse reaction with a relatively low incidence but which is sometimes life-threatening, to highlight the variety of CT manifestations, and to provide advice on regulating the timing and method of glucocorticoid therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, the First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, 215000, China.
- Department of Medical Oncology, the First Affiliated Hospital of Soochow University, Suzhou City Jiangsu Province, 215006, China.
- National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, 215000, China.
- Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou City, Jiangsu Province, 215006, China.
- Department of Radiology, Affiliated Hospital of Jiangnan University, Wuxi City, Jiangsu Province, 214000, China.
- Institute of Medical Imaging, Soochow University, Suzhou City, Jiangsu Province, 215000, China.
ORCID-Profile: Chuhan Wang
Förderung
- the Translational Research Grant of NCRCH
- Gusu Medical Talent of Suzhou City
- Suzhou science and technology development project
- the National Natural Science Foundation of China
- Jiangsu Six Talent Peaks Project
Zitieren
APA
Wang, C., Zhu, H., Huang, H., Sun, Z., Teng, Y., & Li, Y. (2023). Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment. Future Oncology, 19(3), 259-270. https://doi.org/10.2217/fon-2022-0826
Vancouver
Wang C, Zhu H, Huang H, Sun Z, Teng Y, Li Y. Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment. Future Oncology. 2023;19(3):259-270. doi:10.2217/fon-2022-0826
BibTeX
@article{Wang2023,
author = {Wang, Chuhan and Zhu, Hong and Huang, Haiwen and Sun, Zongqiong and Teng, Yue and Li, Yonggang},
title = {Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment},
journal = {Future Oncology},
year = {2023},
volume = {19},
number = {3},
pages = {259--270},
doi = {10.2217/fon-2022-0826}
}
EUVIMED